Neuphoria Therapeutics Inc. Income Statement
NEUP|1 years of annual SEC 10-K data (FY2025-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
Neuphoria Therapeutics Inc. reported $16M in revenue and $369,632 in net loss for FY2025. Its profit margin was -2.4% in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.76 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 |
|---|---|
| Revenue | $15.6M |
| SG&A Expense | $7.8M |
| R&D Expense | $9.0M |
| Operating Income | -$1.1M |
| Income Tax | -$468.4K |
| Net Income | -$369.6K |
| EPS (Basic) | -$18.62 |
| EPS (Diluted) | -$18.62 |
| Shares Outstanding | 1.1M |
| Operating Margin | -7.2% |
| Profit Margin | -2.4% |